Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Shares Shorted: Short Interest Down 87.3% in September

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) was the recipient of a large decrease in short interest during the month of September. As of September 30th, there was short interest totaling 56,158 shares, a decrease of 87.3% from the September 15th total of 440,994 shares. Based on an average daily volume of 119,021 shares, the days-to-cover ratio is presently 0.5 days. Approximately 6.0% of the shares of the stock are short sold.

Matinas Biopharma Trading Down 4.5%

MTNB stock traded down $0.13 during midday trading on Monday, reaching $2.74. The stock had a trading volume of 21,506 shares, compared to its average volume of 138,249. The company’s fifty day simple moving average is $3.03 and its 200 day simple moving average is $6.74. The company has a market cap of $2.69 million, a price-to-earnings ratio of -0.16 and a beta of 2.08. Matinas Biopharma has a 52-week low of $2.26 and a 52-week high of $28.95.

Matinas Biopharma (NYSEAMERICAN:MTNB) last released its earnings results on Thursday, August 13th. The company reported ($3.15) earnings per share (EPS) for the quarter.

About Matinas Biopharma

Matinas BioPharma, Inc is a clinical-stage biotechnology company developing medicines based on its proprietary lipid nanocrystal (LNC) delivery technology. The platform is designed to improve the oral delivery of active pharmaceutical ingredients that may otherwise have limited absorption or require intravenous administration.

The company’s lead program, MAT2203, is an oral formulation of amphotericin B, an antifungal medicine traditionally administered intravenously. Matinas has studied MAT2203 for serious systemic fungal infections, including cryptococcal meningitis, and has evaluated its potential to provide an orally administered alternative with fewer administration-related burdens.